Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Neurology
3
Pipeline Programs
4
Companies
14
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
HYQVIAPhase 35 trials
Active Trials
NCT06747351Recruiting59Est. Jun 2028
NCT06895967Completed30Est. Jul 2025
NCT05755035Completed65Est. Jan 2026
+2 more trials
Octapharma
OctapharmaAustria - Vienna
1 program
1
NewGam 10%Phase 2/31 trial
Active Trials
NCT01225276Terminated2Est. Oct 2012
Biogen
BiogenCAMBRIDGE, MA
1 program
1
Interferon Beta-1aPhase 21 trial
Active Trials
NCT00099489Completed67Est. Feb 2006
argenx
argenxBelgium - Zwijnaarde
1 program
Efgartigimod PH20 SCN/A1 trial
Active Trials
NCT07264426Recruiting200Est. Oct 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
TakedaHYQVIA
TakedaHYQVIA
TakedaHYQVIA
TakedaHYQVIA
TakedaHYQVIA
TakedaHYQVIA
OctapharmaNewGam 10%
BiogenInterferon Beta-1a
TakedaHYQVIA
TakedaHYQVIA
argenxEfgartigimod PH20 SC
TakedaHYQVIA
TakedaHYQVIA
TakedaHYQVIA

Clinical Trials (14)

Total enrollment: 1,159 patients across 14 trials

NCT03116347TakedaHYQVIA

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Start: May 2017Est. completion: Jan 202142 patients
Phase 4Completed
NCT06747351TakedaHYQVIA

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start: May 2025Est. completion: Jun 202859 patients
Phase 3Recruiting
NCT03277313TakedaHYQVIA

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Start: Sep 2017Est. completion: Jul 202244 patients
Phase 3Completed
NCT02955355TakedaHYQVIA

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Start: Nov 2016Est. completion: Jul 202385 patients
Phase 3Completed
NCT02549170TakedaHYQVIA

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start: Dec 2015Est. completion: Feb 2022138 patients
Phase 3Completed
NCT05755035TakedaHYQVIA

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Start: Oct 2023Est. completion: Jan 202665 patients
Phase 2/3Completed
NCT01225276OctapharmaNewGam 10%

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Start: Oct 2011Est. completion: Oct 20122 patients
Phase 2/3Terminated
NCT00099489BiogenInterferon Beta-1a

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start: Feb 2004Est. completion: Feb 200667 patients
Phase 2Completed
NCT06895967TakedaHYQVIA

A Study of TAK-881 and HyQvia in Healthy Adults

Start: Mar 2025Est. completion: Jul 202530 patients
Phase 1Completed
NCT04578535TakedaHYQVIA

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Start: Oct 2020Est. completion: Mar 202251 patients
Phase 1Completed
NCT07264426argenxEfgartigimod PH20 SC

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Start: Aug 2025Est. completion: Oct 2029200 patients
N/ARecruiting
NCT04636502TakedaHYQVIA

Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)

Start: Feb 2021Est. completion: Sep 202196 patients
N/ACompleted
NCT02556775TakedaHYQVIA

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Start: Dec 2015Est. completion: Dec 201916 patients
N/ACompleted
NCT02593188TakedaHYQVIA

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Start: Nov 2015Est. completion: Oct 2021264 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,159 patients
4 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)